Lantheus Holdings Inc
NASDAQ:LNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
US |
|
H
|
Halliburton Co
XHAM:HAL
|
US |
|
I
|
Iridium Communications Inc
SWB:6IC
|
US |
|
N
|
Norsk Hydro ASA
XMUN:NOH1
|
NO |
|
Osmosun SA
F:V05
|
FR |
Lantheus Holdings Inc
Lantheus Holdings makes diagnostic products that help doctors see disease inside the body, especially in cancer and heart imaging. Its main products are imaging agents used with PET, SPECT, ultrasound, and other scans, including the prostate cancer tracer PYLARIFY and the ultrasound contrast agent DEFINITY. These products do not treat patients directly; they help hospitals and imaging centers find and track disease more accurately. The company sells mainly to hospitals, imaging centers, and other healthcare providers that use advanced scans. It makes money by selling these specialty drugs and contrast agents, and in some cases by licensing or partnering around its imaging technologies. Because these products are used before a diagnosis or procedure, Lantheus sits in an important middle step of the healthcare chain between drug makers, scanning equipment, and the clinicians who read the images. What makes the business different is that it focuses on a small set of highly specialized imaging products rather than broad hospital supplies. That means its success depends on how widely doctors adopt its tracers and contrast agents in specific disease areas, especially cancer and cardiology. For investors, Lantheus is best understood as a focused medical imaging company whose value comes from products that improve what doctors can see, not from therapies that directly cure disease.
Lantheus Holdings makes diagnostic products that help doctors see disease inside the body, especially in cancer and heart imaging. Its main products are imaging agents used with PET, SPECT, ultrasound, and other scans, including the prostate cancer tracer PYLARIFY and the ultrasound contrast agent DEFINITY. These products do not treat patients directly; they help hospitals and imaging centers find and track disease more accurately.
The company sells mainly to hospitals, imaging centers, and other healthcare providers that use advanced scans. It makes money by selling these specialty drugs and contrast agents, and in some cases by licensing or partnering around its imaging technologies. Because these products are used before a diagnosis or procedure, Lantheus sits in an important middle step of the healthcare chain between drug makers, scanning equipment, and the clinicians who read the images.
What makes the business different is that it focuses on a small set of highly specialized imaging products rather than broad hospital supplies. That means its success depends on how widely doctors adopt its tracers and contrast agents in specific disease areas, especially cancer and cardiology. For investors, Lantheus is best understood as a focused medical imaging company whose value comes from products that improve what doctors can see, not from therapies that directly cure disease.
Strong start: Lantheus said first-quarter performance was solid across PYLARIFY, NEUROCEQ and DEFINITY, with management calling it a good start to a year focused on commercial execution and regulatory progress.
Guidance held: The company reaffirmed full-year 2026 revenue guidance of $1.4 billion to $1.45 billion and adjusted EPS guidance of $5 to $5.25, saying it wanted to stay prudent early in the year and ahead of a CEO change.
TRUVU launch: FDA approved PYLARIFY TRUVU on March 6, and the company plans a site-by-site conversion beginning in Q4, with meaningful revenue contribution expected in 2027.
Pipeline progress: PNT2003 received tentative FDA approval, while the Actinium PDUFA date was extended 3 months to June 29, 2026 to allow more review of manufacturing information.
NEUROCEQ momentum: NEUROCEQ revenue rose to $35.4 million, up 14.3% sequentially, supported by deeper use in existing accounts, Alzheimer’s therapy adoption and a growing manufacturing footprint.
Competitive watch: Management said it is monitoring PSMA PET competition but does not expect a major new entrant to meaningfully affect 2026; it still sees the PSMA PET market growing in the low teens this year.
